Liver cancer, Secondary cancers
Open
Phase 1/2
This trial is looking at AZD5069 and durvalumab for the most common type of liver cancer called hepatocellular carcinoma (HCC).
It is for people who can’t have surgery to remove the cancer because it has spread. This is .
Cancer Research UK supports this trial.
Recruitment start: 29 April 2022
Recruitment end: 31 December 2025
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Jeff Evans
Cancer Research UK
Cancer Research UK Clinical Trials Unit, Glasgow
NHS Greater Glasgow and Clyde
University of Glasgow
This is Cancer Research UK trial number CRUK/19/014.
Last reviewed: 22 June 2025
CRUK internal database number: 17186
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
